Marie-Ange Massiani

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

Marie Wislez, Julien Mazières, A. Lavolé et al. · Journal for ImmunoTherapy of Cancer · 2022 · 114 citations · Full text

Medicine, Oncology, Chemotherapy +14

Clinical Characteristics of Pneumonic-Type Adenocarcinoma of the Lunga

Marie Wislez, Marie-Ange Massiani, B. Milleron et al. · CHEST Journal · 2003 · 100 citations

Medicine, Oncology, Pathology +13

Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients

Clémence Basse, Sarah Diakite, Vincent Servois et al. · JNCI Cancer Spectrum · 2020 · 60 citations · Full text

Medicine, Infectious Diseases, Molecular Oncology +10

Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab

Coraline Duménil, Marie-Ange Massiani, Jennifer Dumoulin et al. · PLoS ONE · 2018 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)

Marie Wislez, Julien Mazières, A. Lavolé et al. · Annals of Oncology · 2020 · 58 citations

Medicine, Oncology, Thoracic Oncology +10